|Mr. Timothy M. Mayleben||Chief Exec. Officer, Pres and Director||796.44k||N/A||56|
|Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA||Chief Operating Officer and Exec. VP of R&D||487k||N/A||64|
|Dr. Mary P. McGowan M.D.||Chief Medical Officer||481.36k||N/A||57|
|Dr. Roger S. Newton Ph.D., FAHA, FACN||Scientific Advisor and Director||358.58k||N/A||66|
|Mr. Richard B. Bartram||VP of Fin. and Corp. Sec.||N/A||N/A||N/A|
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 9; Compensation: 8.